ライフサイエンスコーパス: pertussis

1 sent targets for therapeutic intervention in pertussis.

2 id and targeted approach to the diagnosis of pertussis.

3 in adaptive immunological memory against B. pertussis.

4 memory induced by natural infection with B. pertussis.

5 or reducing the morbidity and mortality from pertussis.

6 asible and may facilitate early detection of pertussis.

7 ported household contacts with mild/atypical pertussis.

8 ngeal specimens from patients with suspected pertussis, 3.0% (n = 32) were B. pertussis positive and

9 Incidence of whooping cough (pertussis), a bacterial infection of the respiratory tra

10 In response to low temperatures, B. pertussis adapted its fatty acid composition and membran

11 l chains govern the activities of Bordetella pertussis adenylate cyclase toxin (CyaA), Escherichia co

12 B. pertussis also requires a relatively expensive growth me

13 s of maternal Tdap vaccination in preventing pertussis among infants aged <2 months in Argentina.

14 ound modest protection against PCR-confirmed pertussis among older adults (mean age 61 years, range 4

15 ound modest protection against PCR-confirmed pertussis among older adults (mean age, 61 years; range,

16 Little is known about pertussis among pregnant women, a population at increase

17 s) were 150 CFU/ml or 3 fg/mul of DNA for B. pertussis and 1,500 CFU/ml or 10 fg/mul of DNA for B. pa

18 reference assays were 97.1% and 99.0% for B. pertussis and 100% and 99.7% for B. parapertussis The Ar

19 etection (LoDs) were 1,800 CFU.ml(-1) for B. pertussis and 213 CFU.ml(-1) for B. parapertussis The as

20 ces in low-temperature adaptation between B. pertussis and B. bronchiseptica may result from selectiv

21 ries Bordetella Assay, which detects both B. pertussis and B. parapertussis directly from nasopharyng

22 r assays in detecting and differentiating B. pertussis and B. parapertussis in nasopharyngeal swab sp

23 des accurate detection and distinction of B. pertussis and B. parapertussis infections within 2 h.

24 th other classical bordetellae, including B. pertussis and B. parapertussis, something the current va

25 her molecular assays for the detection of B. pertussis and B. parapertussis.

26 om days to hours for detection of Bordetella pertussis and Bordetella parapertussis In this study, we

27 detection and differentiation of Bordetella pertussis and Bordetella parapertussis nucleic acids in

28 Detection of Bordetella pertussis and Bordetella parapertussis using molecular m

29 raction that is central to infection with B. pertussis and other Bordetella species.

30 sign of more effective approaches to control pertussis and other Bordetella-related diseases.

31 cine candidate induces protection against B. pertussis and prevents nasal colonization in animal mode

32 n the lungs of mice during infection with B. pertussis and significantly expanded through local proli

33 monella virulence factors, genes involved in pertussis, and antimicrobial resistance.

34 streptococcus, respiratory syncytial virus, pertussis, and influenza.

35 ols against pneumococcal serotypes, tetanus, pertussis, and varicella despite previous vaccination.

36 o characterize the Fc profile of influenza-, pertussis-, and SARS-CoV-2-specific antibodies transferr

37 during 2008-2014 on the kinetics of maternal pertussis antibodies in unvaccinated women and their inf

38 Pertussis antibody titers are higher in acellular pertus

39 r and different antibody specificities to B. pertussis antigens as compared with the aPV that primari

40 ody levels (p < 0.001) against all tested B. pertussis antigens post-priming compared to 157 infants

41 body levels (P < .001) against all tested B. pertussis antigens postpriming compared to 157 infants r

42 s analysis, potentially novel immunogenic B. pertussis antigens were identified.RESULTSAll BPZE1 vacc

43 rameters: IgG, IgA, and memory B cells to B. pertussis antigens.

44 cohort vaccinated exclusively with acellular pertussis (aP) vaccine.

45 Protection induced by acellular pertussis (aP) vaccines is partial and short-lived, espe

46 In England, acellular pertussis (aP) vaccines replaced whole-cell pertussis (w

47 Infants received either acellular pertussis (aP)- or wP-containing vaccine at 2, 4, 6 and

48 Infants received either acellular pertussis (aP)- or wP-containing vaccine at 2, 4, 6, and

49 ssis antibody titers are higher in acellular pertussis (aP)- than wP-vaccinated infants of immunized

50 ransporter virulence protein from Bordetella pertussis, as measured by small angle X-ray scattering (

51 With the infection rate of Bordetella pertussis at a 60-year high, there is an urgent need for

52 pertussis The assay detected 16/18 unique B. pertussis/B. parapertussis strains.

53 t epidemiologic data and clinical aspects of pertussis, Bordetella biology and pathogenesis, immunolo

54 by infection of the airways with Bordetella pertussis (Bp).

55 ed role in protective immunity to Bordetella pertussis, but this evidence is based largely on periphe

56 sults that were incorrectly identified as B. pertussis by the FilmArray RP and one false-negative res

57 es in the lipid A biosynthesis pathway in B. pertussis cannot handle precursors with a 3OH-C12 chain.

58 Pertussis case patients identified from September 2012 t

59 Hospitalized pertussis cases <=60 days old in England were extracted

60 omatic infection among household contacts of pertussis cases and to explore the published literature

61 nts aged <2 months accounted for 1.6% of all pertussis cases but 29.3% of hospitalizations.

62 revention document a raw proxy for counts of pertussis cases in the U.S., and the Project Tycho (PT)

63 Because of increased numbers of recorded pertussis cases in the United States, this study sought

64 Pertussis cases in women aged 18-44 years with cough ons

65 Of 26259 pertussis cases reported in children (aged <18 years), 2

66 1,582 pertussis cases were identified among women aged 18-44 y

67 During 2000-2016, 339 420 pertussis cases were reported.

68 bclinical infection in household contacts of pertussis cases, which may play a substantial role in th

69 earlier in pregnancy on hospitalized infant pertussis cases.

70 ed MyD88-deficient mice, whereas virulent B. pertussis caused a severe pathological condition and dea

71 of detection was 3.0 x 10(5) CFU/mL with B. pertussis cells in buffer, 6.2 x 10(5) CFU/mL with nasop

72 trong and long-lasting protection against B. pertussis challenge by inducing potent Ab and T cell res

73 piratory syncytial virus A and B, Bordetella pertussis, Chlamydophila pneumoniae, and Mycoplasma pneu

74 Bordetella pertussis colonization can be deliberately induced and l

75 associated with increased risk of confirmed pertussis compared with wP.

76 mptomatic contacts with laboratory-confirmed pertussis, comprising up to 55.6% of those tested.

77 overage in three doses of diphtheria tetanus pertussis containing vaccine between 2013 and 2015.

78 ovement in third dose of diphtheria- tetanus-pertussis-containing vaccine (DTP3) coverage in polio hi

79 rage of the third dose of diphtheria-tetanus-pertussis-containing vaccine (DTP3), which is typically

80 2 months to 11 years who were up to date on pertussis-containing vaccines had a 43%-66% reduced risk

81 In B. pertussis, deletion of the rseA gene results in high tra

82 piratory disease mainly caused by Bordetella pertussis Despite wide global vaccination coverage with

83 of Bordetella and a better understanding of pertussis disease and vaccine performance.

84 mechanisms by which S1PR agonists attenuate pertussis disease are unknown.

85 ther, S1PR agonist AAL-R failed to attenuate pertussis disease in PGLYRP4 knockout (KO) mice.

86 hat S1PR agonist-mediated protection against pertussis disease is PGLYRP4 dependent.

87 has been described after diphtheria-tetanus-pertussis (DTP) vaccination in females.

88 antibody responses to the diphtheria-tetanus-pertussis (DTP) vaccine included in the Expanded Program

89 oxoid present in the diphtheria, tetanus and pertussis (DTP) vaccine.

90 ), such as the standard diphtheria, tetanus, pertussis (DTP)-containing vaccine.

91 stered with either BCG or diphtheria-tetanus-pertussis (DTP)1; and the second or third dose would be

92 d <2 months whose mothers received acellular pertussis during the third trimester and children aged 2

93 With a continuing resurgence in pertussis, efforts should focus on maximizing Tdap uptak

94 tussis Surveillance (EPS) system to describe pertussis epidemiology among pregnant and non-pregnant w

95 ed monitoring is important to further define pertussis epidemiology in pregnant women.

96 used national surveillance data to describe pertussis epidemiology, including patient demographic ch

97 o effective therapies for treating fulminant pertussis exist.

98 pecimens containing as few as 1.8 x 10(6) B. pertussis genomes/mL and showed no false-positives.

99 s against B. pertussis was measured using B. pertussis growth inhibition assay (BGIA).

100 ella pertussis was measured using Bordetella pertussis growth inhibition assay.

101 e lipid A biosynthesis pathway, which, in B. pertussis, has limited chain length specificity.

102 ory tract caused by the bacterium Bordetella pertussis, has reached levels not seen since the 1950s.

103 ldhood immunisation for diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, S

104 ity of postchemotherapy diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenza

105 ld recognize multiple clinical strains of B. pertussis, highlighting the potential of Qbeta-glycan as

106 This national database study compares pertussis hospitalizations among infants before and afte

107 universal tetanus, diphtheria, and acellular pertussis immunisation during pregnancy.

108 The blunting effect of pertussis immunization during pregnancy on infant antibo

109 The blunting effect of maternal pertussis immunization during pregnancy on infant antibo

110 ies had geographic clusters of high rates of pertussis in children ages 10 to 14 years old, consisten

111 number of preterm infants hospitalized with pertussis in England halved after the policy change and

112 s gestation was more effective at preventing pertussis in infant than vaccination during the second t

113 during pregnancy is effective in preventing pertussis in infants aged <2 months in Argentina, with s

114 Evidence suggests that the resurgence of pertussis in many industrialized countries may result fr

115 ansmission of the etiologic agent Bordetella pertussis In response to this escalating public health c

116 red for persistence of the human pathogen B. pertussis in the murine LRT and we provide evidence that

117 g immunity may have had on the resurgence of pertussis in the United States at the community level.

118 The incidence of pertussis in the United States has increased in recent y

119 zymatic activity inhibits phagocytosis of B. pertussis in vitro.

120 owed by a booster dose of tetanus-diphtheria-pertussis inactivated polio vaccine (Tdap) 3 months late

121 of the diphtheria-tetanus toxoids-acellular pertussis-inactivated poliomyelitis-Haemophilus influenz

122 Our analysis suggests that pertussis incidence and clinical characteristics of dise

123 In 2011, Argentina experienced its highest pertussis incidence and mortality rates of the last deca

124 onths, antenatal immunization reduced annual pertussis incidence by 60%, from 780 per 100,000 firstbo

125 auto-correlation corrected linear models for pertussis incidence in 2004-2011 for the entire U.S. and

126 whether Google Trends (GT) search data track pertussis incidence relative to PT data and if sociodemo

127 Average annual pertussis incidence was 5.7/100,000 among pregnant and 7

128 Expression of meningococcal LpxH in B. pertussis indeed resulted in new symmetric lipid A speci

129 Curiously, B. pertussis-infected IFNAR1 knockout mice had wild-type le

130 ng pulmonary transcriptional responses in B. pertussis-infected mice treated with S1PR agonist AAL-R

131 In support of this finding, B. pertussis-infected mice with a knockout mutation in the

132 In B. pertussis-infected mice, lung type I/III IFN responses c

133 alyses were conducted to characterize severe pertussis infection and identify potential risk factors.

134 We conducted a population-based study of pertussis infection and reinfection during a 5-year peri

135 ffects of type I/III IFN signaling during B. pertussis infection and suggest that these pathways repr

136 egulate type I or III IFNs in response to B. pertussis infection and were protected from lethal infec

137 factor A, TcfA) for detection of Bordetella pertussis infection by lateral flow immunoassay (LFIA).

138 ed type I IFN receptor (IFNAR) signaling, B. pertussis infection exacerbated lung inflammatory pathol

139 While characteristics of severe pertussis infection have been described in infants, fewe

140 lung gene expression responses to Bordetella pertussis infection in adult mice, revealing that type I

141 uce pulmonary inflammation during Bordetella pertussis infection in mouse models.

142 LFIA detection of TcfA as a biomarker for B. pertussis infection is feasible and may facilitate early

143 In this analysis, we characterize pertussis infections in hospitalized patients of all age

144 Continued monitoring of severe pertussis infections will be important to help guide pre

145 of life may be the most vulnerable to severe pertussis infections, though hospitalization was reporte

146 rtactin-producing and pertactin-deficient B. pertussis infections.

147 Pertussis is a highly contagious disease for which promp

148 Bordetella pertussis is a human pathogen that can infect the respir

149 Pertussis is a severe respiratory disease mainly caused

150 Bordetella pertussis is among the leading causes of vaccine-prevent

151 The lipopolysaccharide (LPS) of B. pertussis is an attractive antigen for vaccine developme

152 is study, a neonatal mouse model of critical pertussis is characterized, and a central role for pertu

153 omatic nasopharyngeal carriage of Bordetella pertussis is inducible in humans and to define the micro

154 Bordetella pertussis is one of the leading causes of vaccine preven

155 vaccine coverage in many parts of the world, pertussis is resurging in a number of areas in which ace

156 The Gram-negative bacterium Bordetella pertussis is the causative agent of whooping cough, a se

157 ed by the obligate human pathogen Bordetella pertussis is undergoing a worldwide resurgence.

158 ged with a high dose of a highly virulent B. pertussis isolate, they were fully protected against dis

159 Molecular characterization of archived B. pertussis isolates (collected January 2007 to March 2014

160 by the LFIA were conserved in 98% of 954 B. pertussis isolates collected across 12 countries from 19

161 Pertussis-like toxins are secreted as disulfide-bonded h

162 lecular mechanism underpinning activation of pertussis-like toxins, and we also identified difference

163 We conclude that the asymmetry of B. pertussis lipid A is determined by the acyl chain length

164 attempts to modulate the endotoxicity of B. pertussis lipid A, here we expressed the gene encoding L

165 is defect as well as for the asymmetry of B. pertussis lipid A.

166 cells that incorporated 3OH-C12 chains in B. pertussis lipid A.

167 sugars and unusual glycosyl linkages, the B. pertussis LPS is a highly challenging synthetic target.

168 olecular dynamics simulation and modeling, a pertussis-LPS-like pentasaccharide was chemically synthe

169 mpared with B. bronchiseptica Remarkably, B. pertussis maintained the production of virulence factors

170 In response to increases in pertussis morbidity and mortality among young infants, s

171 Cases were identified from linked pertussis notifications and each matched to 3 controls o

172 Cases were identified from linked pertussis notifications and each matched to three contro

173 Most severe and fatal cases of pertussis occur in infants <8 weeks of age, before initi

174 ryngeal samples with previously confirmed B. pertussis or B. parapertussis data and with data from 50

175 Pertussis, or whooping cough, caused by the obligate hum

176 Among 9801 pertussis patients aged >/=3 months, 77.6% were AAV.

177 h suspected pertussis, 3.0% (n = 32) were B. pertussis positive and 0.2% (n = 2) were B. parapertussi

178 nce of mumps in England in the mid-2000s and pertussis post-1980 in the United States.

179 l data is important to evaluate and optimize pertussis prevention and control strategies.

180 ls from the lungs of mice reinfected with B. pertussis produced significantly more IL-17 than gammade

181 VirB/VirD4, E. coli R388 Trw, and Bordetella pertussis Ptl systems support conjugative DNA transfer i

182 st-effectiveness of the program by comparing pertussis-related infant hospitalizations and deaths in

183 Infants aged <1 year are at highest risk for pertussis-related morbidity and mortality.

184 Despite successful vaccination programs, pertussis remains endemic in the United States, and incr

185 Among 15942 cases of pertussis reported, 515 (3.2%) were hospitalized.

186 These CD4 TRM cells were B. pertussis specific and secreted IL-17 or IL-17 and IFN-g

187 Influenza- and pertussis-specific antibodies were actively transferred.

188 ificantly reduced compared to influenza- and pertussis-specific antibodies, and cord titers and funct

189 .RESULTSAll BPZE1 vaccinees showed robust B. pertussis-specific antibody responses with regard to sig

190 Maternal Tdap vaccination inhibited more pertussis-specific responses in wP vaccinated infants co

191 Maternal Tdap vaccination inhibited more pertussis-specific responses in wP-vaccinated infants co

192 trol group of unvaccinated women had highest pertussis-specific responses, persisting until after the

193 ly with non-attenuated, wild type Bordetella pertussis strain B1917.

194 lly with nonattenuated, wild-type Bordetella pertussis strain B1917.

195 Bordetella pertussis strains lacking expression of pertactin, a bac

196 ganisms, but did react with nine distinct B. pertussis strains.

197 e incidence and changing age distribution of pertussis suggest a central role of the transition to ac

198 We used CDC's Enhanced Pertussis Surveillance (EPS) system to describe pertussi

199 ata suggests that GT is a potentially useful pertussis surveillance tool.

200 o a systemic immune response without causing pertussis symptoms.

201 prenatal tetanus, diphtheria, and acellular pertussis (Tdap) vaccination and risk of attention-defic

202 ated with tetanus, diphtheria, and acellular pertussis (Tdap) vaccine during pregnancy in Thailand.

203 id, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine was recommended for all pregnan

204 vaccinated with tetanus-diphtheria-acellular pertussis (Tdap)-vaccine during pregnancy in Thailand.

205 -spatial resolution (5 x 5 km) of diphtheria-pertussis-tetanus (DPT) vaccine coverage and dropout for

206 o Jules Bordet, the discoverer of Bordetella pertussis, the 12th International Bordetella Symposium w

207 Lipid A of Bordetella pertussis, the causative agent of whooping cough, displa

208 nt nasopharyngeal colonization by Bordetella pertussis, the principal causative agent of whooping cou

209 specifically attaches 3OH-C12 chains, in B. pertussis This expression was lethal, suggesting that on

210 Mean anti-pertussis titres were higher by 9.4% (3.3-15.5; p = 0.00

211 Mean anti-pertussis titres were not significantly different in the

212 a may result from selective adaptation of B. pertussis to the human host.

213 B. pertussis uses pertussis toxin (PT) and adenylate cyclase toxin (ACT) t

214 nant aP (r-aP) vaccine including recombinant pertussis toxin (PT) and filamentous hemagglutinin (FHA)

215 sis is characterized, and a central role for pertussis toxin (PT) is described.

216 Antibodies against pertussis toxin (PT), filamentous haemagglutinin (FHA) a

217 Antibodies against pertussis toxin (PT), filamentous hemagglutinin (FHA), a

218 aning immunity to 14 pneumococcal serotypes, pertussis toxin (PT), tetanus toxoid (TT) and varicella,

219 was modestly inhibited by pretreatment with pertussis toxin (PTX), consistent with a minor role for

220 The G(i/o) inhibitor pertussis toxin and inhibitors of PKA and PKC had no eff

221 preterm infants vs term infants, except for pertussis toxin and pneumococcal serotypes 4 and 19F aft

222 andidate containing non-adsorbed recombinant Pertussis Toxin and reduced the amount of antigen dose r

223 However, the increase was inhibited by pertussis toxin as well as by wortmannin but not by AG14

224 was blocked by Cre-induced expression of the pertussis toxin catalytic subunit (PTXa).

225 althy subjects aged 18-45 years with an anti-pertussis toxin IgG concentration of <20 IU/ml were inoc

226 Anti-pertussis toxin IgG seroconversion occurred in nine out

227 nal vaccination results in higher birth anti-pertussis toxin titers in preterm neonates.

228 blockade of G-protein-coupled receptors with pertussis toxin treatment prior to transfer only partial

229 cement of the ASIC currents was resistant to pertussis toxin treatment, suggesting that Galpha (i)/Ga

230 though both these responses are sensitive to pertussis toxin treatment.

231 CB1R antagonist rimonabant and Gi uncoupler pertussis toxin, and absent in Cnr1(-/-) RGCs.

232 ieved protective IgG antibody levels against pertussis toxin, diphtheria, tetanus and 6 of 10 pneumoc

233 atic ADP-ribosyltransferase PtxS1-subunit of pertussis toxin, respectively.

234 Pertussis toxin, which inhibits activation of G(i)/G(o),

235 s also applied for G(i)alpha GTP-loading and pertussis toxin-catalyzed ADP-ribosylation of G(i)alpha,

236 Icatibant caused MC degranulation via a pertussis toxin-sensitive G protein but did not activate

237 t TRPC4 channels are particularly coupled to pertussis toxin-sensitive G(i/o) proteins, with a co-dep

238 l-regulated kinases 1/2 pathways, along with pertussis toxin-sensitive signals.

239 nulation via MRGPRX2, which was abolished by pertussis toxin.

240 ade that was sensitive to ERK inhibitors and pertussis toxin.

241 activity was elevated expressed very little pertussis toxin.

242 lar signal-regulated kinases (ERK) 1/2 or by pertussis toxin.

243 12-h pretreatment of human islets with pertussis-toxin (PTX) improved GSIS and prevented the in

244 Both receptors induced pertussis-toxin (PTX) insensitive inhibition of cyclic A

245 sented evidence consistent with asymptomatic pertussis transmission between household contacts.

246 We simulated pertussis transmission within an individual-based model

247 review reveals a gap in our understanding of pertussis transmission.

248 g vaccine efficacy and protection against B. pertussis transmission.TRIAL REGISTRATIONClinicalTrials.

249 B. pertussis uses pertussis toxin (PT) and adenylate cyclas

250 Inactivated influenza vaccine (IIV) and pertussis vaccination are recommended in pregnancy.

251 onducted in a subgroup of women who received pertussis vaccination during pregnancy to assess whether

252 Adjustment for pertussis vaccination during pregnancy yielded similar r

253 udy assesses the impact of offering maternal pertussis vaccination earlier in pregnancy on hospitaliz

254 ociations were found between maternal IIV or pertussis vaccination in pregnancy and adverse birth out

255 at enrollment, and either tetanus-diphtheria-pertussis vaccination or IIV3 6 months later.

256 In October 2012, a maternal pertussis vaccination program was implemented in England

257 In October 2012 a maternal pertussis vaccination program was introduced in England

258 sus 19.5% of controls, had provider-verified pertussis vaccination, on average 3.2 years earlier.

259 rsus 19.5% of controls had provider-verified pertussis vaccination, on average, 3.2 years earlier.

260 outcomes were maintained after adjusting for pertussis vaccination.

261 50 or later who may have received whole-cell pertussis vaccine (53%; -11% to 80%); p-heterogeneity=0.

262 50 or later who may have received whole-cell pertussis vaccine (53%; -11-80%) (P-heterogeneity = 0.9)

263 tion program of the currently used acellular pertussis vaccine (aPV).

264 at the time of the first diphtheria-tetanus-pertussis vaccine (DTP1) or the first measles-containing

265 We have developed the live attenuated nasal pertussis vaccine BPZE1, currently undergoing clinical e

266 netics of antibody responses to an acellular pertussis vaccine by a genome-wide association study in

267 east 3 doses of diphtheria-tetanus-acellular pertussis vaccine by the end of 15 months of age.

268 ntibody response induced by our epicutaneous Pertussis vaccine candidate containing non-adsorbed reco

269 Pertussis vaccine may induce cross-immunity.

270 eks of age, before initiation of the primary pertussis vaccine series.

271 id, reduced diphtheria toxoid, and acellular pertussis vaccine.

272 the potential of Qbeta-glycan as a new anti-pertussis vaccine.

273 id, reduced diphtheria toxoid, and acellular pertussis) vaccine was recommended for women during each

274 d short-lived immunity elicited by acellular pertussis vaccines and to their inability to prevent nas

275 me countries, nor from ones using whole-cell pertussis vaccines for primary immunization.

276 alyzed 403 cases and 581 971 controls with 4 pertussis vaccines recorded.

277 the workshop "Overcoming Waning Immunity in Pertussis Vaccines" in September 2019 to identify issues

278 ndations that older adults receive acellular pertussis vaccines, data on direct effectiveness in adul

279 global vaccination coverage with efficacious pertussis vaccines, it remains one of the least well-con

280 to compare protection provided by different pertussis vaccines.

281 r high, there is an urgent need for new anti-pertussis vaccines.

282 defects in immunity stimulated by acellular pertussis vaccines.

283 B. pertussis virulence factor tracheal cytotoxin (TCT), a s

284 Adjusted VE against PCR-diagnosed pertussis was 52% (95% CI, 15-73%), nonsignificantly hig

285 Adjusted VE against PCR-diagnosed pertussis was 52% (95%CI 15 to 73%); non-significantly h

286 reventing hospitalization among infants with pertussis was 72% (95% confidence interval [CI], 49%-85%

287 Enhanced innate immune response to B. pertussis was characterized by increased production of p

288 BA and FilmArray RP for the detection of B. pertussis was considered good at 97.7% with a kappa valu

289 No shedding of Bordetella pertussis was detected in systematically collected envir

290 Functionality of antibodies against B. pertussis was measured using B. pertussis growth inhibit

291 nctionality of antibodies against Bordetella pertussis was measured using Bordetella pertussis growth

292 and negative percent agreement (NPA) for B. pertussis were 98.7% and 97.3%, respectively.

293 Finally, coadministration of virulent B. pertussis with BPZE1 did not cause exacerbated outgrowth

294 Cases of pertussis with cough onset from 1 January 2011 through 3

295 fy all children with 2 reported incidents of pertussis with symptom onset between 1 January 2010 and

296 BPZE1 induces protection in mice against B. pertussis within days after vaccination, at a time when

297 ant antibody responses induced by whole-cell pertussis (wP) vaccination is not well-defined.

298 ant antibody responses induced by whole cell pertussis (wP) vaccination is not well-defined.

299 pertussis (aP) vaccines replaced whole-cell pertussis (wP) vaccine in the primary immunization cours

300 NCT02408926.Infant whole-cell pertussis (wP) vaccine responses are blunted after mater